Meeting report: Mode(s) of action of asbestos and related mineral fibers

Environmental Health Perspectives

Volumn 119, Issue 12, 2011, Pages 1806-1810

  Gwinn, Maureen R ^a   Devoney, Danielle ^a   Jarabek, Annie M ^a   Sonawane, Babasaheb ^a   Wheeler, John ^b   Weissman, David N ^c   Masten, Scott ^d   Thompson, Claudia ^e  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b AGENCY FOR TOXIC SUBSTANCES AND DISEASE REGISTRY   (United States)

^c NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^e NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Asbestos; Knowledge gaps; Mineral fibers; Mode of action; Research needs

Indexed keywords

ASBESTOS; MINERAL FIBER;

ADVERSE OUTCOME; ASBESTOSIS; CARCINOGENICITY; DISEASE PREDISPOSITION; DOSE RESPONSE; DOSIMETRY; ENVIRONMENTAL EXPOSURE; GENOTOXICITY; HEALTH HAZARD; HUMAN; LUNG CANCER; LUNG TOXICITY; MALIGNANT MESOTHELIOMA; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; SURFACE PROPERTY; WORKSHOP;

EID: 82755162784     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1003240     Document Type: Review

References (34)

1. Aust AE, Cook PM, Dodson RF. 2011. Morphological and chemical mechanisms of elongated mineral particle toxicities. J Toxicol Environ Health B Crit Rev 14:40-75.
2. Azari MR, Nasermoaddeli A, Movahadi M, Mehrabi Y, Hatami H, Soori H, et al. 2010. Risk assessment of lung cancer and asbestosis in workers exposed to asbestos fibers in brake shoe factory in Iran. Ind Health 48:38-42.
3. Below JE, Cox NJ, Fukagawa NK, Hirvonen A, Testa JR. 2011. Factors that impact susceptibility to fiber-induced health effects. J Toxicol Environ Health B Crit Rev 14:246-266.
4. Blake DJ, Bolin CM, Cox DP, Cardozo-Pelaez F, Pfau JC. 2007. Internalization of Libby amphibole asbestos and induction of oxidative stress in murine macrophages. Toxicol Sci 99:277-288.
5. Blake DJ, Wetzel SA, Pfau JC. 2008. Autoantibodies from mice exposed to Libby amphibole asbestos bind SSA/Ro52-enriched apoptotic blebs of murine macrophages. Toxicology 246:172-179.
6. Bogdanffy MS, Daston G, Faustman EM, Kimmel CA, Kimmel GL, Seed J, et al. 2001. Harmonization of cancer and noncancer risk assessment: proceedings of a consensusbuilding workshop. Toxicol Sci 61:18-31.
7. Brims FJ. 2009. Asbestos-a legacy and a persistent problem. J R Nav Med Serv 95:4-11.
8. Broaddus VC, Everitt JI, Black B, Kane AB. 2011. Nonneoplastic and neoplastic pleural endpoints following fiber exposure. J Toxicol Environ Health B Crit Rev 14:153-178.
9. Bunderson-Schelvan M, Pfau JC, Crouch R, Holian A. 2011. Non-pulmonary outcomes of asbestos exposure. J Toxicol Environ Health B Crit Rev 14:122-152.
10. Burki T. 2010. Health experts concerned over India's asbestos industry. Lancet 375:626-627.
11. Case BW, Abraham J, Meeker G, Pooley F, Pinkerton KE. 2011. Applying definitions of "asbestos" to environmental and "low-dose" exposure levels and health effects, particularly malignant mesothelioma. J Toxicol Environ Health B Crit Rev 14:3-39.
12. Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, et al. 2007. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 13:5076-5081.
13. Eastmond DA, Hartwig A, Anderson D, Anwar WA, Cimino MC, Dobrev I, et al. 2009. Mutagenicity testing for chemical risk assessment: update of the WHO/IPCS Harmonized Scheme. Mutagenesis 24:341-349.
14. Goodman JE, Nascarella MA, Valberg PA. 2009. Ionizing radiation: a risk factor for mesothelioma. Cancer Causes Control 20:1237-1254.
15. Guyton KZ, Barone S Jr, Brown RC, Euling SY, Jinot J, Makris S. 2008. Mode of action frameworks: a critical analysis. J Toxicol Environ Health B Crit Rev 11:16-31.
16. Gwinn MR. 2011. Multiple modes of action of asbestos and related mineral fibers. J Toxicol Environ Health B Crit Rev 14:1-2.
17. Huang SXL, Jaurand MC, Kamp DW, Whysner J, Hei TK. 2011. Role of mutagenicity in mineral fiber-induced carcino genicity and other diseases. J Toxicol Environ Health B Crit Rev 14:179-245.
18. IARC (International Agency for Research on Cancer). 1977. Asbestos: Summary of Data Reported and Evaluation. IARC Monogr Eval Carcinog Risk Hum 14.
19. IOM (Institute of Medicine) and National Research Council. 2009. Review of the NIOSH Roadmap for the Research on Asbestos Fibers and Other Elongate Mineral Particles. Washington, DC:National Academies Press. Available: http://www.nap.edu/openbook.php?record_id=12697 [accessed 19 May 2011].
20. Kamp DW. 2009. Asbestos-induced lung disease: an update. Transl Res 153:143-152.
21. Li G, Passebosc-Faure K, Feng G, Lambert C, Cottier M, GentilPerret A, et al. 2007. MN/CA9: a potential gene marker for detection of malignant cells in effusions. Biomarkers 12:214-220.
22. Lippmann M. 1990. Effects of fiber characteristics on lung deposition, retention, and disease. Environ Health Perspect 88:311-317.
23. Mossman BT, Lippmann M, Hesterberg TW, Kelsey KT, Barchowsky A, Bonner JC. 2011. Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos. J Toxicol Environ Health B Crit Rev 14:76-121.
24. NIOSH (National Institute for Occupational Safety and Health). 2011. Current Intelligence Bulletin 62: Asbestos Fibers and Other Elongate Mineral Particles: State of the Science and Roadmap for Research. Version 4. April 2011. Available: http://www.cdc.gov/niosh/docket/archive/docket099C.html [accessed 15 May 2011].
25. Park EK, Hannaford-Turner KM, Hyland RA, Johnson AR, Yates DH. 2008. Asbestos-related occupational lung diseases in NSW, Australia and potential exposure of the general population. Ind Health 46:535-540.
26. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, et al. 2008. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 85:265-272.
27. Pfau JC, Sentissi JJ, Li S, Calderon-Garciduenas L, Brown JM, Blake DJ. 2008. Asbestos-induced autoimmunity in C57BL/6 mice. J Immunotoxicol 5:129-137.
28. Sanchez VC, Pietruska JR, Miselis NR, Hurt RH, Kane AB. 2009. Biopersistence and potential adverse health impacts of fibrous nanomaterials: what have we learned from asbestos? Wiley Interdiscip Rev Nanomed Nanobiotechnol 1:511-529.
29. Scherpereel A, Lee YC. 2007. Biomarkers for mesothelioma. Curr Opin Pulm Med 13:339-443.
30. Selikoff IJ, Hammond EC, Churg J. 1968. Asbestos exposure, smoking and neoplasia. JAMA 204:106-112.
31. Straif K, Benbramin-Tallaa L, Baan R, Grosse Y, Secretan B, El Ghissassi F, et al. 2009. Special report: policy. A review of human carcinogens-part C: metals, arsenic, dusts and fibres. Lancet 10:453-454.
32. Ugolini D, Neri M, Ceppi M, Cesario A, Dianzani I, Filiberti R, et al. 2008. Genetic susceptibility to malignant mesothelioma and exposure to asbestos: the influence of the familial factor. Mutat Res 658:162-171.
33. U.S. Environmental Protection Agency. 2005. Guidelines for carcinogen risk assessment. EPA/630/P-03/001F. Available: www.epa.gov/ttn/atw/cancer_guidelines_final_3-25-05.pdf [accessed 22 November 2010].
34. Yang H, Testa JR, Carbone M. 2008. Mesothelioma epidemiology, carcinogenesis and pathogenesis. Curr Treat Options Oncol 9:147-157.